About Us
Fund
Support
Return
Our Companies
left
About Us
Our Companies
Our DNA
Fund
Our Investment Strategy
Our Investors
Our Funds
Our Charity Fund
Support
Our Value Creation
Our Team and Network
Return
Return to Investors
Return to People
Return to Society
right
News
JOIN OUR TEAM
Investor Portal
Contact
NEWS
Our Latest News
ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera
View All
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
ARCHIMED completes seventh acquisition for NAMSA, the world leader in Medical Device testing services
March
27,
2023
Majority owner ARCHIMED and partners CAPZA and Siparex finance add-on acquisition by European safety testing company – and French market leader – CARSO
March
16,
2023
ARCHIMED buys WiQo, a pioneer in the field of aesthetic medicine
March
9,
2023
ARCHIMED invests in PlasmidFactory, a German gene and cell therapy specialist
October
7,
2022
ARCHIMED Impact Report 2021 – Investing for Better Healthcare: a Global Challenge
October
4,
2022
ARCHIMED acquires Nasdaq-listed Natus Medical Incorporated in $1.1 billion take-private deal
July
21,
2022
<
1
2
3
4
…
13
>
368
